Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Diagnostic and Therapeutic Trends in Alzheimer's Disease (Technical Insights) | Jun 2008 | £4,110 | 100% |
| Alzheimer's Disease - Pipeline Review H2 2011 |
Sep 2011 | £315 | 98% |
| Alzheimer’s Disease Patients & Market Worldwide Future Scenario (2010 – 2015) & Drugs Analysis |
Jun 2011 | £600 | 98% |
| Alzheimer's Disease Global Clinical Trials Review H2 2011 |
Oct 2011 | £630 | 96% |
| CNS Market Trends, 2007 to 2010 Key Market Forecasts and Growth Opportunities |
Jun 2007 | £995 | 95% |
| The 10th International Conference on Alzheimer's and Parkinson's Diseases Post-Conference Review and Analysis |
Mar 2011 | £630 | 93% |
| Neurodegenerative Drugs | Apr 2010 | £2,500 | 92% |
| Alzheimer's disease Technologies, Markets and Companies |
Jan 2012 | £2,265 | 91% |
| Alzheimer's and Parkinson's Diseases A Global Update of Market Trends & Opportunities |
Nov 2009 | £1,895 | 91% |
| CoMentis, Inc. – Product Pipeline Review H2 2011 |
Dec 2011 | £315 | 90% |
| Analysis of Deals in Neurodegenerative Diseases | Jul 2010 | £2,800 | 90% |
| Alzheimer's and Parkinson's Disease | May 2008 | £2,500 | 88% |
| The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis |
Dec 2009 | £2,215 | 87% |
| Therapeutics for Memory and Cognition Disorders | Apr 2009 | £3,065 | 86% |
| Alzheimers Disease Antibodies Competitor Analysis |
Jul 2008 | £83 | 85% |
| Alzheimer's Disease Market Forecast | Nov 2010 | £9,615 | 85% |
| Epidemiology: Alzheimer's Disease | Dec 2010 | £3,605 | 85% |
| Understanding Alzheimer's Disease Risk Factors, Genetics and Clinical Research |
Nov 2010 | £93 | 84% |
| Early Diagnosis of Alzheimer's Disease Benefits, Challenges and Recent Developments |
Mar 2011 | £315 | 84% |
| Increasing Disease Burden of Alzheimer's Disease Is There a Solution in Sight? |
Mar 2011 | £315 | 84% |
| Alzheimer Disease Therapy Area Pipeline Report | Mar 2011 | £945 | 84% |
| Prescribing Influences: Alzheimer's Disease Alleviating symptoms remains the goal for prescribers |
Jun 2011 | £2,405 | 84% |
| Image-Based Biomarkers in Alzheimer's Disease 2011 |
Feb 2011 | £350 | 84% |
| Alzheimer's Disease Pipeline Assessment and Market Forecasts to 2017 |
Nov 2010 | £1,265 | 84% |
| ProteoTech, Inc. – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 84% |
| Alzheimer's Disease Autoantibodies, Vaccines and Therapeutic Antibodies Pipeline, 2011 |
Mar 2011 | £1,500 | 83% |
| U.S. Alzheimer's Disease Medication Market | Aug 2010 | £3,795 | 83% |
| Chinese Markets for Alzheimer Disease Drugs | Apr 2009 | £2,530 | 83% |
| Alzheimer's Disease Biomarkers in Cerebrospinal Fluid and Blood 2011 |
Feb 2011 | £650 | 83% |
| Alzheimer’s Disease Immunotherapy Pipeline Vaccines, Therapeutic Antibodies and Emerging Strategies |
Jul 2010 | £1,500 | 83% |
